| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $967,033 | 2 | 100 |
| Versant Venture Capital VI, L.P. | 10 percent owner | 0 | $0 | 2 | $967,033 | $-967,033 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Over the last 12 months, insiders at Tempest Therapeutics, Inc. have bought $0 and sold $967,033 worth of Tempest Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tempest Therapeutics, Inc. have bought $2.56M and sold $967,033 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 35,000 shares for transaction amount of $73,850 was made by Brady Stephen R (President and CEO) on 2024‑07‑03.
| 2024-08-12 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 387,999 2.043% | $1.10 | $426,993 | -9.57% | |
| 2024-08-08 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 400,000 1.814% | $1.35 | $540,040 | -35.02% | |
| 2024-07-03 | Brady Stephen R | President and CEO | 35,000 0.1539% | $2.11 | $73,850 | +446.21% | ||
| 2024-07-02 | Whiting Samuel | Chief Medical Officer | 4,672 0.0207% | $2.13 | $9,951 | +443.63% | ||
| 2024-06-28 | Trojanowski Justin | Corporate Controller | 7,500 0.0338% | $2.16 | $16,200 | +426.48% | ||
| 2022-04-29 | Woiwode Thomas | 2.12M 11.9674% | $2.36 | $5M | +391.55% | |||
| 2022-01-07 | Dubensky Thomas W. | President | 2,000 0.0288% | $4.78 | $9,560 | -27.97% | ||
| 2022-01-06 | Whiting Samuel | Chief Medical Officer | 1,700 0.0243% | $4.80 | $8,168 | -28.78% | ||
| 2016-06-01 | Dipp Michelle | Chief Executive Officer | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | ||
| 2016-06-01 | ALDRICH RICHARD | director | 425,000 1.3568% | $7.00 | $2.98M | -53.63% | ||
| 2016-05-18 | Dipp Michelle | Chief Executive Officer | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | ||
| 2016-05-18 | ALDRICH RICHARD | director | 20,000 0.0671% | $7.86 | $157,200 | -53.14% | ||
| 2016-05-17 | Dipp Michelle | Chief Executive Officer | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | ||
| 2016-05-17 | ALDRICH RICHARD | director | 20,000 0.0677% | $7.56 | $151,200 | -50.67% | ||
| 2016-05-16 | Dipp Michelle | Chief Executive Officer | 20,000 0.0668% | $7.69 | $153,800 | -51.69% | ||
| 2016-05-13 | Dipp Michelle | Chief Executive Officer | 16,295 0.055% | $7.06 | $115,043 | -46.48% | ||
| 2016-05-13 | ALDRICH RICHARD | director | 16,295 0.055% | $7.06 | $115,043 | -46.48% | ||
| 2016-05-12 | Dipp Michelle | Chief Executive Officer | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | ||
| 2016-05-12 | ALDRICH RICHARD | director | 19,800 0.0679% | $6.84 | $135,352 | -43.52% | ||
| 2016-05-11 | Dipp Michelle | Chief Executive Officer | 20,000 0.0709% | $7.64 | $152,800 | -47.08% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 209941 5.1363% | $1.32M | 0 | 2 | |
| Westphal Christoph H | 3820571 93.4712% | $24.05M | 2 | 0 | ||
| Longwood Fund, L.P. | 10 percent owner | 3820571 93.4712% | $24.05M | 2 | 0 | |
| Woiwode Thomas | 2118644 51.8332% | $13.34M | 1 | 0 | ||
| ALDRICH RICHARD | director | 962056 23.5369% | $6.06M | 29 | 0 | <0.0001% |
| Dipp Michelle | Chief Executive Officer | 962056 23.5369% | $6.06M | 29 | 0 | <0.0001% |
| Malley Thomas | director | 122200 2.9897% | $769,249.00 | 3 | 0 | <0.0001% |
| Dubensky Thomas W. | President | 113343 2.773% | $713,494.19 | 1 | 0 | |
| Brady Stephen R | President and CEO | 46376 1.1346% | $291,936.92 | 1 | 0 | +446.21% |
| Trojanowski Justin | Corporate Controller | 22168 0.5423% | $139,547.56 | 1 | 0 | +426.48% |
| KOZIN MARC D | director | 20553 0.5028% | $129,381.14 | 3 | 0 | <0.0001% |
| Stock Harald F. | director | 13022 0.3186% | $81,973.49 | 10 | 0 | |
| CAPELLO JEFFREY D | director | 11111 0.2718% | $69,943.75 | 1 | 0 | |
| Whiting Samuel | Chief Medical Officer | 9573 0.2342% | $60,262.04 | 2 | 0 | +443.63% |
| FISHER MARY | director | 6415 0.1569% | $40,382.43 | 1 | 0 | <0.0001% |
| Young Jeffrey E | Chief Financial Officer | 3750 0.0917% | $23,606.25 | 2 | 0 | <0.0001% |
| CHAPMAN PAUL W.D. | Chief Operating Officer | 3100 0.0758% | $19,514.50 | 1 | 0 | <0.0001% |
| Harding David | Chief Commercial Officer | 2290 0.056% | $14,415.55 | 1 | 0 | |
| BLECK CHRISTOPHER A | Chief Commercial Officer | 2000 0.0489% | $12,590.00 | 1 | 0 | |
| TZIANABOS ARTHUR | President and CSO | 400 0.0098% | $2,518.00 | 3 | 0 | <0.0001% |
| McNeely Theresa | EVP, Chief Comm. Officer | 400 0.0098% | $2,518.00 | 2 | 0 | <0.0001% |
$155,580,641 | 77 | -24.21% | $23.91M | |
Tempest Therapeutics, Inc. (TPST) | $17,268,389 | 57 | -18.16% | $25.73M |
$6,204,522 | 45 | 1.91% | $27M | |
$395,438 | 43 | -21.25% | $22.47M | |
$22,323,743 | 39 | 23.92% | $31.78M | |
$1,995,470 | 22 | 14.01% | $22.81M | |
$36,557,692 | 17 | 3.38% | $33.19M | |
$139,007,129 | 16 | 47.16% | $27.24M | |
$156,484,110 | 12 | 52.55% | $27.07M | |
$19,300,035 | 11 | 45.88% | $31.78M | |
$189,648 | 9 | -52.20% | $23.88M | |
$1,472,879 | 6 | -13.59% | $30.92M | |
$26,000,000 | 5 | -56.00% | $22.21M | |
$147,504 | 5 | -36.70% | $22.2M | |
$1,184,658 | 4 | -22.17% | $22.68M | |
$157,740 | 3 | 153.95% | $27.14M | |
$100,266 | 2 | 3.17% | $29.3M | |
$30,190 | 1 | -42.39% | $21.75M | |
$500,000 | 1 | -22.94% | $22.3M |
| Increased Positions | 12 | +35.29% | 3M | +626.57% |
| Decreased Positions | 12 | -35.29% | 91,542 | -17.55% |
| New Positions | <1 | New | 6 | New |
| Sold Out Positions | 11 | Sold Out | 90,860 | Sold Out |
| Total Postitions | 34 | 0% | 4M | +609.02% |
| Versant Venture Management, Llc | $1,886.00 | 6.74% | 269,763 | +269,763 | New | 2024-12-31 |
| Blackrock, Inc. | $302.00 | 1.08% | 43,191 | +742 | +1.75% | 2025-03-31 |
| Jane Street Group, Llc | $265.00 | 0.95% | 37,929 | +37,929 | New | 2024-12-31 |
| Fmr Llc | $232.00 | 0.83% | 33,224 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $190.00 | 0.68% | 27,251 | +10,323 | +60.98% | 2024-12-31 |
| Ubs Group Ag | $105.00 | 0.38% | 15,051 | +14,405 | +2,229.88% | 2024-12-31 |
| Millennium Management Llc | $102.00 | 0.36% | 14,577 | +14,577 | New | 2024-12-31 |
| Vanguard Group Inc | $95.00 | 0.34% | 13,553 | 0 | 0% | 2024-12-31 |
| Xtx Topco Ltd | $86.00 | 0.31% | 12,369 | +10,524 | +570.41% | 2024-12-31 |
| Fil Ltd | $70.00 | 0.25% | 9,967 | 0 | 0% | 2024-12-31 |